Correction to: Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Works matching IS 03407004 AND DT 2022 AND VI 71 AND IP 9
Results: 21
1
2
Murine myeloid derived suppressor cells possess a range of suppressive mechanisms—Granzyme B is not among them.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2255, doi. 10.1007/s00262-022-03162-z
- By:
- Publication type:
- Article
3
Comparison of characteristics and tumor targeting properties of extracellular vesicles derived from primary NK cells or NK-cell lines stimulated with IL-15 or IL-12/15/18.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2227, doi. 10.1007/s00262-022-03161-0
- By:
- Publication type:
- Article
4
Phase I study of expanded natural killer cells in combination with cetuximab for recurrent/metastatic nasopharyngeal carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2277, doi. 10.1007/s00262-022-03158-9
- By:
- Publication type:
- Article
5
Targeting transforming growth factor-β2 by antisense oligodeoxynucleotide accelerates T cell-mediated tumor rejection in a humanized mouse model of triple-negative breast cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2213, doi. 10.1007/s00262-022-03157-w
- By:
- Publication type:
- Article
6
Immune escape mechanism behind resistance to anti-PD-1 therapy in gastrointestinal tract metastasis in malignant melanoma patients with multiple metastases.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2293, doi. 10.1007/s00262-022-03154-z
- By:
- Publication type:
- Article
7
Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2117, doi. 10.1007/s00262-022-03153-0
- By:
- Publication type:
- Article
8
Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2185, doi. 10.1007/s00262-022-03152-1
- By:
- Publication type:
- Article
9
Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2169, doi. 10.1007/s00262-022-03151-2
- By:
- Publication type:
- Article
10
GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2267, doi. 10.1007/s00262-022-03150-3
- By:
- Publication type:
- Article
11
Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2127, doi. 10.1007/s00262-022-03149-w
- By:
- Publication type:
- Article
12
Inflammasome activation, NLRP3 engagement and macrophage recruitment to tumor microenvironment are all required for Salmonella antitumor effect.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2141, doi. 10.1007/s00262-022-03148-x
- By:
- Publication type:
- Article
13
Antibody-dependent cellular phagocytosis of tropomyosin receptor kinase C (TrkC) expressing cancer cells for targeted immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2099, doi. 10.1007/s00262-022-03147-y
- By:
- Publication type:
- Article
14
The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2151, doi. 10.1007/s00262-022-03146-z
- By:
- Publication type:
- Article
15
Interleukin-12 as an in situ cancer vaccine component: a review.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2057, doi. 10.1007/s00262-022-03144-1
- By:
- Publication type:
- Article
16
Adoptive cell therapies in thoracic malignancies.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2077, doi. 10.1007/s00262-022-03142-3
- By:
- Publication type:
- Article
17
Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2109, doi. 10.1007/s00262-022-03141-4
- By:
- Publication type:
- Article
18
Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2239, doi. 10.1007/s00262-022-03140-5
- By:
- Publication type:
- Article
19
Enhancing the anti-leukemia immunity of acute lymphocytic leukemia-derived exosome-based vaccine by downregulation of PD-L1 expression.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2197, doi. 10.1007/s00262-021-03138-5
- By:
- Publication type:
- Article
20
Pancreatic cancer survival prediction via inflammatory serum markers.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2287, doi. 10.1007/s00262-021-03137-6
- By:
- Publication type:
- Article
21
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 9, p. 2067, doi. 10.1007/s00262-021-03130-z
- By:
- Publication type:
- Article